Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
FAIL · Does not pass the screen
29.95 USD
At the last full screen 2026-09-15
Screened 2026-09-15 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 29.95 against the desk's fair-value range, base estimate 68.76, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price29.95 USD
Fair value68.76
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markdown28.75+4.2% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Viking Therapeutics, Inc. holds its Markdown at $29.95. The statistical read favours the buyers, held for 173 days.
As held on the ledger · 2026-09-15
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 173 days
Price at the screen
$29.95
Valuation
N/A trailing · -6.93 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.68
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.02%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
75.44%
Below 33%
Interest-bearing cash and securities are 75.4% of assets, above the one-third limit.
Fail
Receivables
23.17%
Below 49%
Money owed to the company is 23.2% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 19 covering, consensus Strong Buy. The average target sits +217% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
A clinical bet on unproven metabolic drugs
Picture a lab team chasing one thyroid hormone candidate through years of trials with no product on the market yet. Viking fits that picture exactly. Revenue sits at zero, margins at zero and return on equity at minus seventy percent, so the business remains a pure cash burner at this stage. Analyst price targets look ambitious but sit far ahead of any approved therapy or recurring income.
We pass for a clear reason. The ethical screen returns insufficient data because basic financial ratios are missing, and our opportunity rating is none. Without those numbers we cannot judge either the durability of any future moat or the real governance behind the pipeline.
Risk sits high. Clinical failure, dilution and regulatory setbacks are the normal path for firms at this point, and the negative forward earnings multiple simply reflects that the company has yet to turn a profit. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VKTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-16Markdown$29.95-12.6%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93.
2026-08-16Markdown$34.26+19.2%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 19.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93.
2026-07-18Markdown$28.75+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 5%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (19 analysts) rates it strong buy, with a mean price target of $93.
2026-07-03Markdown$28.75+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$28.75Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
